Free Trial
NASDAQ:LSTA

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Lisata Therapeutics logo
$2.68 +0.05 (+1.90%)
As of 01:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Lisata Therapeutics Stock (NASDAQ:LSTA)

Key Stats

Today's Range
$2.49
$3.09
50-Day Range
$2.10
$2.94
52-Week Range
$1.87
$4.20
Volume
438,584 shs
Average Volume
30,653 shs
Market Capitalization
$23.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Lisata Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

LSTA MarketRank™: 

Lisata Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 465th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lisata Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lisata Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.66) to ($2.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lisata Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lisata Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lisata Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Lisata Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.46% of the float of Lisata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lisata Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lisata Therapeutics has recently decreased by 0.32%, indicating that investor sentiment is improving.
  • Dividend Yield

    Lisata Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lisata Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.46% of the float of Lisata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lisata Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lisata Therapeutics has recently decreased by 0.32%, indicating that investor sentiment is improving.
  • News Sentiment

    Lisata Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Lisata Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of Lisata Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 8.94% of the stock of Lisata Therapeutics is held by institutions.

  • Read more about Lisata Therapeutics' insider trading history.
Receive LSTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LSTA Stock News Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
Lisata Therapeutics (NASDAQ:LSTA) Trading Down 3% - Here's What Happened
Lisata Therapeutics, Inc. (LSTA) - Yahoo Finance
See More Headlines

LSTA Stock Analysis - Frequently Asked Questions

Lisata Therapeutics' stock was trading at $2.98 at the start of the year. Since then, LSTA stock has decreased by 10.1% and is now trading at $2.68.

Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced its earnings results on Thursday, May, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.02.
Read the conference call transcript
.

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN).

Company Calendar

Last Earnings
5/08/2025
Today
7/15/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LSTA
CIK
320017
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+470.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.99 million
Net Margins
N/A
Pretax Margin
-2,027.00%
Return on Equity
-61.37%
Return on Assets
-53.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.52
Quick Ratio
7.52

Sales & Book Value

Annual Sales
$1 million
Price / Sales
22.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.49 per share
Price / Book
0.75

Miscellaneous

Outstanding Shares
8,616,000
Free Float
7,832,000
Market Cap
$22.66 million
Optionable
Not Optionable
Beta
1.03
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:LSTA) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners